We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01236404
First Posted: November 8, 2010
Last Update Posted: May 21, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
PhaseBio Pharmaceuticals Inc.
November 5, 2010
November 8, 2010
May 21, 2013
November 2010
November 2011   (Final data collection date for primary outcome measure)
Safety/Tolerability [ Time Frame: Screening to Final Visit (up to approximately 10 weeks for SAD and 14 weeks for MAD) ]
Safety will be evaluated by analyses of incidence of adverse events of interest (possibly related to the class of drug) and other adverse events. Vital signs, ECGs and safety laboratory parameters will also be presented.
Safety/Tolerability [ Time Frame: Duration of study ]
Safety and tolerability of single and multiple ascending doses of PB1023.
Complete list of historical versions of study NCT01236404 on ClinicalTrials.gov Archive Site
  • Pharmacokinetic Profile [ Time Frame: SAD: Pre-dose, 1, 4, 8, and 12 hours post-dose and Day 1, 2, 3, 5, 7, 10, 14, 21 and 28. MAD: Pre-dose, 1, 4, 8, and 12 hours post-dose and Day 1, 2, 3, 5, pre-dose Days 7, 14 and 21 and at 1, 4, 8, and 12 hours post-dose and Day 22, 23, 26, 28, 35, 42, ]
    To characterize the PK profile of PB1023 after single and multiple ascending doses of PB1023. The following parameters will be evaluated: t1/2, AUC(inf), AUC(0-t), Tmax, Cmax, Elimination Rate Constant, Clearance and Distribution.
  • Pharmacodynamic Response [ Time Frame: Fasting plasma glucose collected the day before dosing and with PK samples, excluding day of dosing. SAD MMTT to occur on day 0 and 2, MAD MMTT to occur on Day 0 and 22 with continuous glucose monitoring on Day -8/-7 to Day 0 and on Day 21 to Day 28. ]
    To assess the pharmacodynamic response of various single and multiple doses of PB1023 (daily fasting plasma glucose and serial glucose (and continuous monitoring as defined in time frame), c-peptide and insulin levels in response to a liquid mixed meal tolerance test (MMTT) pre and post dose) on subjects washed off their baseline oral antihyperglycemic agents.
  • Pharmacokinetic Profile [ Time Frame: 28 days after last dose ]
    To characterize the PK profile of PB1023 after single and multiple ascending doses of PB1023.
  • Pharmacodynamic Response [ Time Frame: Through 28 days after last dose ]
    To assess the pharmacodynamic respone of various single and multiple doses of PB1023 (daily fasting plasma glucose and serial glucose, c-peptide and insulin levels in response to a liquid mixed meal tolerance test (MMTT) pre and post dose) on subjects washed off their baseline oral antihyperglycemic agents.
Not Provided
Not Provided
 
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)

Primary objective:

To evaluate the safety and tolerability of single and multiple ascending doses of PB1023 administered as a subcutaneous (SC) injection in adult subjects with T2DM.

Secondary objectives:

  1. To characterize the pharmacokinetic profile of PB1023 after single and multiple ascending doses of PB1023.
  2. To assess the pharmacodynamic response of various single and multiple doses of PB1023 (daily fasting plasma glucose, and serial glucose, c-peptide and insulin levels in response to a liquid Mixed Meal Tolerance Test (MMTT).
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
  • Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
    Once weekly injections for up to four weeks
  • Experimental: PB1023 Injection
    Subcutaneous injection PB1023
    Interventions:
    • Drug: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
    • Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
  • Placebo Comparator: Placebo (0.9% Sodium Chloride Injection)
    Subcutaneous Injection Placebo
    Interventions:
    • Drug: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
    • Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
November 2011
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or post menopausal or surgically sterile females age 18-75 years of age inclusive.
  • Diagnosed with T2DM for > or = 6 months with HbA1c > or = 6.0% but < or = 9.0% while taking stable doses of one oral antihyperglycemic agent but < or = 8.5% when taking two oral antihyperglycemic agents for up to a maximum of 3 months prior to screening.
  • Fasting Plasma glucose between 115 mg/dL and 269 mg/dL.
  • Fasting C-peptide of > or = 0.8 ng/mL.
  • BMI < or = 40 kg/m2.
  • Otherwise stable health except for T2DM.

Exclusion Criteria:

  • Currently taking a non-oral antihyperglycemic agent.
  • Have taken a PPARg agonist within 90 days of screening.
  • Known allergy to an approved or investigational GLP-1 receptor analog/agonist.
  • Unstable cardiovascular disease as defined in clinical protocol.
  • History, symptoms or signs of pancreatitis or severe gastrointestinal disease.
  • Personal or family history of medullary thyroid tumors history of Multiple Endocrine Neoplasia Syndrome Type 2.
  • Poor glucose control as defined in clinical protocol.
  • Clinically significant renal and/or hepatic dysfunction as defined in clinical protocol.
  • Absolute requirement for corticosteroids or received systemic steroids within 90 days prior to PB1023 administration.
  • Pregnant or lactating females.
  • Known history or active alcohol or drug abuse within 12 months prior to screening.
  • Positive for HIV, Hepatitis B surface antigen or Hepatitis C antibodies.
  • Participating in any other study within 30 days prior to screening.
  • Other medical or psychiatric condition which in the opinion of the investigator would place the subject at increased risk.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01236404
PB1023-PT-CL-0001
Yes
Not Provided
Not Provided
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals Inc.
Not Provided
Principal Investigator: Mark Matson, M.D. Prism Research
PhaseBio Pharmaceuticals Inc.
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP